There is a particular kind of industrial story that never makes the front pages because nothing in it explodes, defaults or gets nationalised. The European specialty chemicals sector is living that story now. Since January 2024, Lumera has logged sixty-one significant carve-outs, site sales and ownership changes in European specialty chemicals. The aggregate enterprise value is a little over €23 billion. The defining feature is not the volume. It is who is selling, and at what multiple.
The sellers, overwhelmingly, are the Mittelstand — second- and third-generation family companies with one or two plants, €40 to 200 million in revenue, and a product list that reads like the index of a chemistry textbook. The buyers, in 74 percent of the transactions, are financial sponsors or sponsor-backed platforms. And the multiples tell you everything about the power balance: median EV/EBITDA of 6.8 in the 2024–25 sample, against 9.4 for comparable assets in 2021.
Three shocks in forty months
The sequence is well known but worth setting down in order, because the consolidation is its logical conclusion. First, the gas shock of 2022 took European energy costs to structurally three to four times American and Middle Eastern levels, and specialty chemistry is, for all its talk of innovation, an energy-conversion business. Second, Chinese producers — running new capacity built for an export market that partly evaporated — pushed into exactly the mid-complexity molecules where the Mittelstand earned its margin. Third, interest costs returned, and a generation of owners who had planned to hand the plant to their children discovered their children had watched them work seventy-hour weeks through a decade of crises and chosen psychiatry or software instead.
The sellers did their grieving in 2023. What remains is arithmetic: a plant that cannot beat Chinese cash costs at European energy prices is worth what a consolidator will pay for its order book.
The sponsor playbook, to be fair, is more constructive than the caricature. The platforms we track are not stripping assets; they are re-siting them. Procurement moves to leverage energy contracts none of the family firms could have negotiated alone. Overlapping sales forces are merged. Product lines are cut from three hundred SKUs to eighty, and the survivors get process investment. Our interviews with twelve platform CEOs describe the same operating thesis: European specialty cannot win on molecule cost, so it wins on qualification depth — aerospace, pharma and semiconductor grades where a decade of audit history is the moat.
The risk sits in the leverage. A 6.8× purchase financed at senior-plus-unitranche levels assumes margin recovery that our chemicals margin tracker does not yet show. If Chinese export pressure persists into 2027, the consolidation vintage of 2024–25 becomes the restructuring vintage of 2028. The quiet story gets loud, eventually. These stories always do.